NCT04626908View on ClinicalTrials.gov

Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 20, 2020

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2023

Conditions
Relapsed and RefractoryLymphoid Hematological Malignancies
Interventions
DRUG

GC022F CAR-T cells

Each subject receive GC022F CAR-T cells by intravenous infusion

Trial Locations (1)

310003

The first affiliated hospital of medical college of zhejiang university, Hangzhou

Sponsors
All Listed Sponsors
collaborator

Gracell Biotechnology Ltd.

OTHER

lead

He Huang

OTHER

NCT04626908 - Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter